About
evitria provides recombinant antibody expression and related protein production services using CHO cells. It serves therapeutic R&D and academic researchers with custom antibody formats and research reagents. The company presents itself as a global antibody expression service provider.
Services
Recombinant Ab Production Service
Produces recombinant antibodies in CHO cells for research and therapeutic development projects.
Afucosylated Ab Service
Produces afucosylated antibodies for projects that require enhanced effector function.
Fc-silenced Ab Service
Produces Fc-silenced antibodies for applications requiring reduced immune activation.
Bispecific Ab Production Service
Produces bispecific and multispecific antibodies in recombinant formats.
HTP Production Service
Provides high-throughput antibody production for larger project volumes.
Other Protein Production Service
Offers production of other proteins beyond antibodies.
Therapeutic Antibody Development & Production
Supports therapeutic antibody development with specific antibodies and production services.
Antibody Production for Academic Research
Supports university researchers with recombinant antibody production for academic research.
7 more services
- eviSIMILAR Recombinant Antibody Analogs
- eviCONTROL Isotype Controls
- Recombinant Antibody Production Service
- Afucosylated Antibody Expression Service
- Fc-silenced Antibody Expression Service
- Bispecific Antibody Production Service
- High-Throughput Antibody Production Service
- Turnaround
- Projects begin within 24 hours of approval
- Delivery in as little as 4 weeks
Capabilities
- Assays and studies
- Antibodies
- CHO
- Bispecifics
- Mammalian expression
- In vivo
- Scale and capacity
- 140,000+ production runs
- More than 23,000 antibodies / antibody-based molecules expressed and purified
Modalities and species
- Modalities
- Antibody
- Bispecific
- Recombinant protein
- Species and models
- CHO cells
- Human
- Mouse–human
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Company
- Type
- CRO
- Founded
- 2010
- Quality
- Low endotoxin levels (<1 EU/mg)
Locations
- Address
- Brunaustrasse 185 8951 Zurich-Fahrweid Switzerland UID CHE-115.416.195 CR CH-
- Sites
- Zurich-Fahrweid, Switzerland
- Serves
- Global, biotech and pharma worldwide, Switzerland to the world
Public records
- Wikidata
- Q140834071 source